bluebird bio (NASDAQ:BLUE) Price Target Increased to $12.00 by Analysts at Bank of America
bluebird bio (NASDAQ:BLUE – Free Report) had its price objective boosted by Bank of America from $11.00 to $12.00 in a research note issued to investors on Monday morning, Benzinga reports. Bank of America currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently issued reports on the stock. […]
More Stories
US Inflation Slows to Lowest Level Since February 2021
By Andrew Moran The U.S. annual inflation rate eased to its lowest level in more than four years, even as...
Jane Street Group LLC Grows Stake in Gerdau S.A. (NYSE:GGB)
Jane Street Group LLC increased its holdings in Gerdau S.A. (NYSE:GGB – Free Report) by 221.1% during the fourth quarter,...
Amazon.com, Inc. (NASDAQ:AMZN) Position Decreased by First Commonwealth Financial Corp PA
First Commonwealth Financial Corp PA lessened its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 1.0% during the fourth quarter, Holdings Channel.com...
Regal Investment Advisors LLC Sells 8,509 Shares of Amazon.com, Inc. (NASDAQ:AMZN)
Regal Investment Advisors LLC lowered its position in Amazon.com, Inc. (NASDAQ:AMZN) by 16.2% in the 4th quarter, HoldingsChannel.com reports. The...
Finer Wealth Management Inc. Has $9.72 Million Stake in Amazon.com, Inc. (NASDAQ:AMZN)
Finer Wealth Management Inc. boosted its holdings in shares of Amazon.com, Inc. (NASDAQ:AMZN) by 1.4% in the 4th quarter, according...
Avenir Corp Decreases Stock Position in Amazon.com, Inc. (NASDAQ:AMZN)
Avenir Corp decreased its stake in Amazon.com, Inc. (NASDAQ:AMZN) by 3.4% during the fourth quarter, Holdings Channel.com reports. The institutional...